In summary, these findings suggest that low-dose IL-12 by RB-312 synergizes with anti-PD-L1 to induce superior tumor suppression when secreting nanoscale levels of IL-12 undetectable in the peripheral circulation. Here, CD274 is linked to neoplasm.